share_log

Biodexa Pharmaceuticals | EFFECT: Others

Biodexa Pharmaceuticals | EFFECT: Others

Biodexa Pharmaceuticals | EFFECT:其他
美股sec公告 ·  05/03 06:06
Moomoo AI 已提取核心訊息
The United States Securities and Exchange Commission (SEC) has declared that Biodexa Pharmaceuticals Plc's submission has become effective as of May 2, 2024. The submission, identified by accession number 0001214659-24-007804 and file number 333-272693, was categorized under the submission type POS AM. This notice of effectiveness by the SEC is a significant regulatory milestone for Biodexa Pharmaceuticals.
The United States Securities and Exchange Commission (SEC) has declared that Biodexa Pharmaceuticals Plc's submission has become effective as of May 2, 2024. The submission, identified by accession number 0001214659-24-007804 and file number 333-272693, was categorized under the submission type POS AM. This notice of effectiveness by the SEC is a significant regulatory milestone for Biodexa Pharmaceuticals.
美國證券交易委員會(SEC)宣佈,Biodexa Pharmicals Plc的申請已於2024年5月2日生效。該提交的材料以入庫號0001214659-24-007804進行識別,文件號爲333-272693,歸類爲提交類型 POS AM。美國證券交易委員會的這份生效通知是Biodexa製藥公司重要的監管里程碑。
美國證券交易委員會(SEC)宣佈,Biodexa Pharmicals Plc的申請已於2024年5月2日生效。該提交的材料以入庫號0001214659-24-007804進行識別,文件號爲333-272693,歸類爲提交類型 POS AM。美國證券交易委員會的這份生效通知是Biodexa製藥公司重要的監管里程碑。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息